Deutsche Biotech Innovativ AG

Deutsche Biotech Innovativ AG ("DBI") is a biotechnology company that uses innovative blood biomarkers to research and clinically develop unique therapeutic solutions for serious diseases for which there are currently no satisfactory medical solutions. The focus is on active substances for the indications sepsis and cancer. The company's lead product is the patented compound adrecizumab for reducing mortality from organ failure in septic shock. Adrecizumab has successfully passed the preclinical phase and will be tested in a Phase I study starting in 2015.

The preclinical and clinical studies are mainly conducted by project companies in which DBI AG holds a stake. DBI AG currently holds 26 percent of AdrenoMed AG, 25 percent of Oncoprevent GmbH, 50 percent of My Life Diagnostics GmbH and 100 percent of AngioBiomed GmbH.

DBI aims to further expand its active ingredient pipeline and invests in the research and development of active ingredients that have a high unique selling proposition.

The two board members of DBI, Dr. Bernd Wegener and Dr. Andreas Bergmann, have many years of experience in the field of biotechnology. Both were part of the founding and management teams respectively of B.R.A.H.M.S. AG, a highly successful biotechnology company specializing in the determination of blood serum levels for the treatment of serious diseases, which was sold in 2009 for approximately 330 million euros. Dr. Bernd Wegener is a member of the Executive Board of the German Pharmaceutical Industry Association.